Review: Multiple DAA Regimens Effective for HCV Genotype 1

Share this content:
Review: Multiple DAA Regimens Effective for HCV Genotype 1
Review: Multiple DAA Regimens Effective for HCV Genotype 1

TUESDAY, March 21, 2017 (HealthDay News) -- For hepatitis C virus (HCV) genotype 1 infection, multiple direct-acting antiviral (DAA) regimens show high rates of safety, tolerability, and efficacy, according to a review published online March 21 in the Annals of Internal Medicine.

Oluwaseun Falade-Nwulia, M.B.B.S., M.P.H., from the Johns Hopkins University School of Medicine in Baltimore, and colleagues conducted a systematic literature review to examine the efficacy and safety of oral DAAs for treatment of persons with chronic HCV infection. Data were included for 42 studies of controlled and single-group registered clinical trials of adults with HCV infection.

The researchers found that for patients with HCV genotype 1 infection without cirrhosis, including those with HIV co-infection, six DAA regimens showed high sustained virologic response (SVR) rates (>95 percent). Limited effective treatments were found for HCV genotype 3 infection (two DAA regimens). Compared with other populations, patients with hepatic decompensation, especially those with Child-Turcotte-Pugh class C disease, had lower SVR rates (78 to 87 percent). For certain DAA regimens and patient groups, the addition of ribavirin was associated with increased SVR rates. Low rates were seen for serious adverse events and treatment discontinuation (less than 10 percent in the general population); more mild or moderate adverse events were seen for regimens that included ribavirin versus those that did not.

"Multiple oral DAA regimens show high rates of safety, tolerability, and efficacy for treatment of HCV genotype 1 infection, particularly among persons without cirrhosis," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract/Full Text
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »